Pliant Therapeutics To Participate In Upcoming Virtual Investor Conferences
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology firm specializing in fibrosis treatments, will participate in investor conferences during September 2020. Key events include Citi's 15th Annual BioPharma Conference from September 8-11, where Scott Turner, Ph.D., will discuss COVID-19 therapeutics on September 9 at 9:50 a.m. EDT. Additionally, the company will attend Cantor Fitzgerald's Virtual Global Healthcare Conference from September 15-17. More details and access to presentations can be found on the Pliant Therapeutics Investors page.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that management will be participating in the following investor conferences in September 2020:
- Citi's 15th Annual BioPharma Conference on September 8-11, 2020. Pliant's Scott Turner, Ph.D., will be on a panel discussing COVID-19 therapeutics on Wednesday, September 9 at 9:50 a.m. EDT.
- Cantor Fitzgerald's Virtual Global Healthcare Conference on September 15-17, 2020.
Company presentations and webcast replays will be available directly on the conference event platform or the Pliant Therapeutics Investors page: https://ir.pliantrx.com/events-and-presentations.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include those regarding our research and potential antifibrotic benefits, are subject to risks and uncertainties identified under the heading "Risk Factors" included in our quarterly report on Form 10-Q for the quarter ended June 30, 2020 and in future filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.
Investor Contact:
Media Contact:
Cambria Fuqua
Canale Communications
cambria@canalecomm.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/pliant-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-301124274.html
SOURCE Pliant Therapeutics, Inc.
FAQ
What investor conferences is Pliant Therapeutics participating in September 2020?
When will Scott Turner speak at the Citi BioPharma Conference?
What is the focus of Pliant Therapeutics?
What are Pliant's lead product candidates?
What is the stock symbol for Pliant Therapeutics?
